CN105037271B - 一种多取代2‑氨基咪唑化合物的制备方法 - Google Patents
一种多取代2‑氨基咪唑化合物的制备方法 Download PDFInfo
- Publication number
- CN105037271B CN105037271B CN201510406762.6A CN201510406762A CN105037271B CN 105037271 B CN105037271 B CN 105037271B CN 201510406762 A CN201510406762 A CN 201510406762A CN 105037271 B CN105037271 B CN 105037271B
- Authority
- CN
- China
- Prior art keywords
- formula
- preparation
- reaction
- carbodiimide
- iii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- -1 polysubstituted 2-aminoimidazole compound Chemical class 0.000 title abstract description 6
- 238000006243 chemical reaction Methods 0.000 claims abstract description 39
- 150000001718 carbodiimides Chemical class 0.000 claims abstract description 20
- JKANAVGODYYCQF-UHFFFAOYSA-N prop-2-yn-1-amine Chemical compound NCC#C JKANAVGODYYCQF-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000002798 polar solvent Substances 0.000 claims abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 10
- 238000007363 ring formation reaction Methods 0.000 claims abstract description 7
- 238000012544 monitoring process Methods 0.000 claims abstract description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 32
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 24
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 21
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 21
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical group CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 18
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 15
- 239000000463 material Substances 0.000 claims description 15
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 11
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 claims description 10
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 10
- DEPDDPLQZYCHOH-UHFFFAOYSA-N 1h-imidazol-2-amine Chemical class NC1=NC=CN1 DEPDDPLQZYCHOH-UHFFFAOYSA-N 0.000 claims description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 238000004587 chromatography analysis Methods 0.000 claims description 8
- 239000012141 concentrate Substances 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- 238000013019 agitation Methods 0.000 claims description 6
- 235000019270 ammonium chloride Nutrition 0.000 claims description 6
- 239000003208 petroleum Substances 0.000 claims description 6
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 6
- NHOWDZOIZKMVAI-UHFFFAOYSA-N (2-chlorophenyl)(4-chlorophenyl)pyrimidin-5-ylmethanol Chemical compound C=1N=CN=CC=1C(C=1C(=CC=CC=1)Cl)(O)C1=CC=C(Cl)C=C1 NHOWDZOIZKMVAI-UHFFFAOYSA-N 0.000 claims description 5
- 125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 239000012044 organic layer Substances 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 4
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Natural products CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 4
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 4
- 150000007530 organic bases Chemical class 0.000 claims description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 4
- 238000000926 separation method Methods 0.000 claims description 4
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 3
- 230000035484 reaction time Effects 0.000 claims description 3
- 238000002390 rotary evaporation Methods 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 claims description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 238000012805 post-processing Methods 0.000 claims description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 2
- RPDAUEIUDPHABB-UHFFFAOYSA-N potassium ethoxide Chemical compound [K+].CC[O-] RPDAUEIUDPHABB-UHFFFAOYSA-N 0.000 claims description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical group [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 claims description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 2
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 claims description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 2
- 125000003944 tolyl group Chemical group 0.000 claims description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 2
- 229910000404 tripotassium phosphate Inorganic materials 0.000 claims description 2
- 238000010792 warming Methods 0.000 claims description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 claims 2
- LCPVQAHEFVXVKT-UHFFFAOYSA-N 2-(2,4-difluorophenoxy)pyridin-3-amine Chemical compound NC1=CC=CN=C1OC1=CC=C(F)C=C1F LCPVQAHEFVXVKT-UHFFFAOYSA-N 0.000 claims 1
- 238000001704 evaporation Methods 0.000 claims 1
- 230000008020 evaporation Effects 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- CHQMHPLRPQMAMX-UHFFFAOYSA-L sodium persulfate Substances [Na+].[Na+].[O-]S(=O)(=O)OOS([O-])(=O)=O CHQMHPLRPQMAMX-UHFFFAOYSA-L 0.000 claims 1
- 239000002994 raw material Substances 0.000 abstract description 10
- 239000003054 catalyst Substances 0.000 abstract description 4
- 229910000510 noble metal Inorganic materials 0.000 abstract description 3
- 239000012295 chemical reaction liquid Substances 0.000 abstract 1
- 230000007613 environmental effect Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 238000004809 thin layer chromatography Methods 0.000 abstract 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 32
- 238000005160 1H NMR spectroscopy Methods 0.000 description 16
- 239000000243 solution Substances 0.000 description 13
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 12
- 238000003786 synthesis reaction Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 6
- 241001269238 Data Species 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 150000002460 imidazoles Chemical class 0.000 description 4
- HJJXBJQKMCQJNN-UHFFFAOYSA-N 5-methyl-N-phenyl-1H-imidazol-2-amine Chemical class N(C1=CC=CC=C1)C=1NC=C(N=1)C HJJXBJQKMCQJNN-UHFFFAOYSA-N 0.000 description 3
- CTTARLKQNGBGLI-UHFFFAOYSA-N C1(=CC=CC=C1)NC=1NC=C(N=1)Cl Chemical class C1(=CC=CC=C1)NC=1NC=C(N=1)Cl CTTARLKQNGBGLI-UHFFFAOYSA-N 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- RGCBEUKPJDJRRW-UHFFFAOYSA-N 2-nitrooxirane Chemical compound [O-][N+](=O)C1CO1 RGCBEUKPJDJRRW-UHFFFAOYSA-N 0.000 description 1
- LWLACWHQQIAWBR-UHFFFAOYSA-N 4,5-dimethyl-n,1-diphenylimidazol-2-amine Chemical class C=1C=CC=CC=1N1C(C)=C(C)N=C1NC1=CC=CC=C1 LWLACWHQQIAWBR-UHFFFAOYSA-N 0.000 description 1
- ZEVPZYCPBCTGOJ-UHFFFAOYSA-N CN(C(c(nc1)c[n]2c1ncc2-c1ccc(C(F)(F)F)cc1)=O)c1ncc[n]1C Chemical compound CN(C(c(nc1)c[n]2c1ncc2-c1ccc(C(F)(F)F)cc1)=O)c1ncc[n]1C ZEVPZYCPBCTGOJ-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 239000003905 agrochemical Substances 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 229910052746 lanthanum Inorganic materials 0.000 description 1
- FZLIPJUXYLNCLC-UHFFFAOYSA-N lanthanum atom Chemical compound [La] FZLIPJUXYLNCLC-UHFFFAOYSA-N 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- YWOITFUKFOYODT-UHFFFAOYSA-N methanol;sodium Chemical group [Na].OC YWOITFUKFOYODT-UHFFFAOYSA-N 0.000 description 1
- MOFPFEWBBPFVME-UHFFFAOYSA-N n'-(4-methoxyphenyl)methanediimine Chemical compound COC1=CC=C(N=C=N)C=C1 MOFPFEWBBPFVME-UHFFFAOYSA-N 0.000 description 1
- DCSWTDASUHYHTA-UHFFFAOYSA-N n'-(4-methylphenyl)methanediimine Chemical compound CC1=CC=C(N=C=N)C=C1 DCSWTDASUHYHTA-UHFFFAOYSA-N 0.000 description 1
- MDBAAYRCFODAFZ-UHFFFAOYSA-N n'-phenylmethanediimine Chemical compound N=C=NC1=CC=CC=C1 MDBAAYRCFODAFZ-UHFFFAOYSA-N 0.000 description 1
- HVSCSPHJFJDZCZ-BARZBYPCSA-N n-[(e)-3-[2-amino-4-[(z)-1-(2-amino-1h-imidazol-5-yl)-3-[(4,5-dibromo-1h-pyrrole-2-carbonyl)amino]prop-1-enyl]-1h-imidazol-5-yl]prop-2-enyl]-4,5-dibromo-1h-pyrrole-2-carboxamide Chemical compound N1C(N)=NC(C(=C\CNC(=O)C=2NC(Br)=C(Br)C=2)\C2=C(N=C(N)N2)\C=C\CNC(=O)C=2NC(Br)=C(Br)C=2)=C1 HVSCSPHJFJDZCZ-BARZBYPCSA-N 0.000 description 1
- HVSCSPHJFJDZCZ-UHFFFAOYSA-N nagelamide C Natural products N1C(N)=NC=C1C(C1=C(NC(N)=N1)C=CCNC(=O)C=1NC(Br)=C(Br)C=1)=CCNC(=O)C1=CC(Br)=C(Br)N1 HVSCSPHJFJDZCZ-UHFFFAOYSA-N 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- BHAAPTBBJKJZER-UHFFFAOYSA-N p-anisidine Chemical compound COC1=CC=C(N)C=C1 BHAAPTBBJKJZER-UHFFFAOYSA-N 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 239000010970 precious metal Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
本发明提供了一种式(III)所示多取代2‑氨基咪唑化合物的制备方法:在非质子极性溶剂中,25~125℃温度条件下,式(I)所示炔丙胺和式(II)所示碳二亚胺在碱性物质的作用下进行环合反应,TLC跟踪监测至反应完全,之后反应液经后处理,得到所述多取代2‑氨基咪唑化合物;本发明反应原料廉价易得,反应过程无需贵金属催化剂,反应条件温和,本发明方法绿色环保,原子经济性高。
Description
(一)技术领域
本发明涉及一种多取代2-氨基咪唑化合物的制备方法。
(二)背景技术
氨基咪唑是一种重要的含氮唑类化合物,该类化合物在医药、农药、染料和材料等众多领域被广泛应用。2-氨基咪唑化合物呈现出如抗菌、抗癌和抗病毒等多种生物活性,因而是新药研究开发的重要领域之一。例如,如下式所示的Nagelamide C含有2-氨基咪唑片段的分子具有多种生物活性,化合物A则可以用来治疗寄生虫病。
现有技术中合成多取代2-氨基咪唑主要有以下几种方法:
例如反应式(1):1,2-二羰基化合物与胍缩合产生的中间产物再经贵金属钯催化加氢还原得到相应的产物(J.Org.Chem.1979,44,818.)。
Koji Kitajma et al1978
该方法的优点是原料易得,但同时存在着反应路线较长和催化剂昂贵的缺点,最主要的不足是只能制备4,5-二取代2-氨基咪唑或者无取代的2-氨基咪唑,而无法实现全取代氨基咪唑的合成。
例如反应式(2):丙炔胺在金属银盐的催化下与碳二亚胺环化生成的中间体经过脱保护和异构化制备3,4,5-三取代-2-氨基咪唑化合物。此类反应也有用其他金属诸如镧和钛催化的合成路线报道(Angew.Chem.,Int.Ed.2010,49,9465.)。
Erik V.Van der Eycken et al2010
该合成方法的优点是能得到多取代氨基咪唑,但同时存在着合成路线长和需要贵金属催 化等缺点。
例如反应式(3):最近,浙江大学俞永平等人报道了以硝基环氧乙烷、伯胺和氰胺为底物一步制备多取代氨基咪唑的高效合成方法(Org.Lett.2015,17,1157.)。
Yongping Yu et al2015
该反应具有高效合成的优点,但同时也存在底物氰胺毒性大以及反应产生的亚硝酸具有致癌毒性等缺点,因此实现工业化生产的可能性较小。
(三)发明内容
本发明目的是提供一种操作简单、原子经济好、不需要贵金属催化剂、反应收率高、生产成本低和环境友好的多取代2-氨基咪唑化合物的制备方法。
为实现上述目的,本发明采用的技术方案是:
一种式(III)所示多取代2-氨基咪唑化合物的制备方法,所述制备方法为:在非质子极性溶剂中,25~125℃温度条件下,式(I)所示炔丙胺和式(II)所示碳二亚胺在碱性物质的作用下进行环合反应,TLC跟踪监测至反应完全,之后反应液经后处理,得到所述多取代2-氨基咪唑化合物;
所述非质子极性溶剂为甲苯、二甲基亚砜、N,N-二甲基甲酰胺、乙腈或四氢呋喃;所述碱性物质为叔丁醇钾、乙醇钠、乙醇钾、甲醇钠、K3PO4、KOH、NaOH、K2CO3、Na2CO3或Cs2CO3;所述式(I)所示炔丙胺与式(II)所示碳二亚胺的投料物质的量之比为1:0.8~1.2;所述式(II)所示碳二亚胺与碱性物质的投料物质的量之比为1:1.0~1.8;
式(II)或式(III)中,R1、R2各自独立为:氢、苯基、对甲基苯基、对甲氧基苯基、对氯苯基、对溴苯基或C4-C10烷基;优选苯基、对甲基苯基、对氯苯基、对溴苯基或C4-C6烷基;特别优选对氯苯基或环己烷基;
式(I)或式(III)中,R3、R4各自独立为:氢或C1-C6烷基;优选氢或C1-C4烷基;特别优选氢或甲基。
本发明所述制备方法,推荐所述非质子极性溶剂的体积用量以式(II)所示碳二亚胺的物质的量计为4~7mL/mmol。
优选所述非质子极性溶剂为二甲基亚砜或N,N-二甲基甲酰胺。
优选所述碱性物质为甲醇钠、NaOH、KOH或Na2CO3。
优选所述式(II)所示碳二亚胺与碱性物质的投料物质的量之比为1:1.0。
通常所述反应在25~125℃下反应2~10h;优选在60~100℃下反应2~6h。
本发明所述反应液后处理的方法为:反应完成后,待反应液冷却至室温,搅拌下向反应液中加入15wt%氯化铵水溶液调节pH至7.0~7.2,然后用乙酸乙酯萃取,萃取所得有机层合并后,经饱和食盐水洗涤、无水硫酸钠干燥、旋转蒸发浓缩得到浓缩物,取浓缩物用体积比10~5:1的石油醚和有机碱混合液作为展开剂进行薄层色谱法分离,得到所述多取代-2- 氨基咪唑化合物;所述有机碱为三乙胺、吡啶、N-甲基吗啉或四甲基乙二胺。
具体的,推荐本发明所述式(III)所示多取代2-氨基咪唑化合物的制备方法为:
将式(I)所示炔丙胺与非质子极性溶剂混合,然后缓慢滴加式(II)所示碳二亚胺,滴完后在25~40℃下搅拌反应1h,再加入碱性物质,升温至70~90℃搅拌反应2~4h,TLC跟踪监测至反应完全,待反应液冷却至室温,在搅拌下向反应液中加入15wt%氯化铵水溶液调节pH至7.0~7.2,然后用乙酸乙酯萃取三次,萃取所得有机层合并后,经饱和食盐水洗涤、无水硫酸钠干燥、旋转蒸发浓缩得到浓缩物,取浓缩物用体积比10:1的石油醚和三乙胺混合液作为展开剂进行薄层色谱法分离,得到所述多取代-2-氨基咪唑化合物;
所述非质子极性溶剂为二甲基亚砜或N,N-二甲基甲酰胺;所述碱性物质为甲醇钠、NaOH、KOH或Na2CO3;所述式(I)所示炔丙胺与式(II)所示碳二亚胺的投料物质的量之比为1:0.8~1.2;所述式(II)所示碳二亚胺与碱性物质的投料物质的量之比为1:1.0;所述非质子极性溶剂的体积用量以式(II)所示碳二亚胺的物质的量计为4~7mL/mmol。
与现有技术相比,本发明的有益效果主要体现在:
(1)本发明反应原料易得,无毒害、价格便宜;
(2)反应不需要贵金属催化剂,更为绿色环保,降低成本;
(3)反应条件相对温和;
(4)相对于传统合成方法,本方法原子经济性高,原料(I)和(II)中的所有原子均保留至产物之中,没有原子损失。
综上,本发明方法反应高效经济且产率高,与已有方法比较具有明显的优点,且具备大规模生产可能性。
(四)具体实施方式
下面结合具体实施例对本发明进行进一步描述,但本发明的保护范围并不仅限于此。
实施例1:5-甲基-1-苯基-2-苯氨基咪唑的合成
(1)向25mL圆底烧瓶中依次加入0.055g(1mmol)炔丙胺,4mL干燥的二甲基亚砜(DMSO),在25℃时,磁力搅拌下滴加苯基碳二亚胺0.194g(1mmol)。搅拌1小时后,加入0.04g(1mmol)氢氧化钠,逐渐升温至80℃进行环合反应,以薄层色谱法(TLC)跟踪反应进程直至原料完全消失,约4小时反应结束;
(2)将反应液冷却至室温,在搅拌下向反应液中加入质量浓度15%的氯化铵水溶液调节pH至7.0-7.2后,用乙酸乙酯萃取三次,每次30mL乙酸乙酯,合并有机层并用10mL饱和食盐水洗涤一次后,再经无水硫酸钠干燥、蒸除溶剂后用石油醚:三乙胺=10:1(体积比)为展开剂薄层色谱法分离,得到上述5-甲基-1-苯基-2-苯氨基咪唑(1a)0.187g,收率为75%。 1H NMR和13C NMR数据如下:
1H NMR(500MHz,CDCl3)δ7.52–7.41(m,3H),7.29–7.24(m,2H),7.17(d,J=3.3Hz,4H),6.91–6.84(m,1H),6.67(s,1H),4.64(s,1H),2.00(s,3H).13C NMR(125MHz,CDCl3)δ143.9,140.5,134.4,130.0,129.3,129.0,127.8,124.7,121.6,119.9,117.6,10.3.
实施例2:5-甲基-1-对甲基苯基-2-对甲基苯氨基咪唑的合成
(1)向25mL圆底烧瓶中依次加入0.055g(1mmol)炔丙胺,4mL干燥的二甲基亚砜(DMSO),在25℃时,磁力搅拌下滴加对甲基苯基碳二亚胺0.222g(1mmol)。搅拌1小时后,加入0.056g(1mmol)氢氧化钾,逐渐升温至80℃进行环合反应,以薄层色谱法(TLC)跟踪反应进程直至原料完全消失,约4小时反应结束;
(2)将反应液冷却至室温,在搅拌下向反应液中加入质量浓度15%的氯化铵水溶液调节pH至7.0-7.2后,用乙酸乙酯萃取三次,每次30mL乙酸乙酯,合并有机层并用10mL饱和食盐水洗涤一次后,再经无水硫酸钠干燥、蒸除溶剂后用石油醚:三乙胺=10:1(体积比)为展开剂薄层色谱法分离,得到上述5-甲基-1-对甲基苯基-2-对甲基苯氨基咪唑(1b)0.193g,收率为70%。1H NMR和13C NMR数据如下:
1H NMR(500MHz,CDCl3)1H NMR(500MHz,CDCl3)δ7.33(s,2H),7.26-7.09(m,4H),7.04(d,J=5.9Hz,2H),6.66(s,1H),5.67(s,1H),2.45(d,J=5.8Hz,3H),2.27(d,J=5.8Hz,3H),2.00(d,J=5.6Hz,3H).13C NMR(125MHz,CDCl3)δ144.1,139.0,138.8,132.2,130.5,129.8,129.3,127.5,123.9,121.8,116.4,21.0,20.4,10.0.
实施例3:5-甲基-1-对氯苯基-2-对氯苯氨基咪唑的合成
以炔丙胺(0.055g,1.0mmol)和对氯苯基碳二亚胺(0.263g,1.0mmol)为原料,按实施例1所述的制备方法。经分离得液体产物5-甲基-1-对氯苯基-2-对氯苯氨基咪唑(1c)0.27g,收率为85%。1H NMR和13C NMR数据如下:
1H NMR(500MHz,CDCl3)1H NMR(500MHz,CDCl3)δ7.55–7.46(m,2H),7.26–7.18(m,4H),7.18–7.14(m,2H),6.67(s,1H),5.75(s,1H),2.01(d,J=0.6Hz,3H).13C NMR(125MHz,CDCl3)δ143.2,140.1,135.3,133.4,130.4,129.1,128.9,125.5,124.5,122.6,117.5,10.2.
实施例4:5-甲基-1-环己基-2-环己基氨基咪唑的合成
以炔丙胺(0.055g,1.0mmol)和环己基碳二亚胺(DCC,0.226g,1.1mmol)为原料,环合反应温度升高至100℃,反应时间延长至6小时,其它按实施例2所述的制备方法。经 分离得液体产物5-甲基-1-环己基-2-环己基氨基咪唑(1d)0.156g,收率为60%。1H NMR和13CNMR数据如下:
1H NMR(500MHz,CDCl3)1H NMR(500MHz,CDCl3)δ6.65(s,1H),5.25(s,1H),3.54-3.52(m,1H),2.56-2.54(m,1H),2.01(d,J=0.6Hz,3H),1.90-1.78(m,4H),1.71-1.48(m,4H),1.53-1.44(m,8H),1.26-1.12(m,4H).,13C NMR(125MHz,CDCl3)δ143.6,140.4,135.8,58.8,54.7,33.4,25.7,25.1,10.3.
实施例5:4,5-二甲基-1-苯基-2-苯氨基咪唑的合成
以3-丁炔-2-胺(0.069g,1.0mmol)和苯基基碳二亚胺(0.194g,1.0mmol)为原料,环合反应温度升高至110℃,反应时间延长至6小时,其它按实施例1所述的制备方法。经分离得液体产物4,5-二甲基-1-苯基-2-苯氨基咪唑(1e)0.160g,收率为61%。1H NMR和13CNMR数据如下:
1H NMR(500MHz,CDCl3)δ7.51–7.40(m,3H),7.28–7.24(m,2H),7.18(d,J=3.3Hz,4H),6.91–6.84(m,1H),4.63(s,1H),2.23(s,3H),2.00(s,3H).13C NMR(125MHz,CDCl3)δ143.9,140.5,134.4,130.0,129.3,129.0,127.8,124.7,121.6,119.9,117.6,12.1,10.3.
实施例6:5-甲基-1-对甲氧基苯基-2-对甲氧基苯氨基咪唑的合成
以炔丙胺(0.055g,1.0mmol)和对甲氧基苯基碳二亚胺(0.254g,1.0mmol)为原料,按实施例1所述的制备方法。经分离得液体产物5-甲基-1-对甲氧基苯基-2-对甲氧基苯氨基咪唑(1f)0.185g,收率为60%。1H NMR和13C NMR数据如下:
1H NMR(500MHz,CDCl3)1H NMR(500MHz,CDCl3)δ7.25(d,J=9.0Hz,2H),7.20(d,J=8.9Hz,2H),7.02(d,J=8.9Hz,2H),6.79(d,J=9.0Hz,2H),6.60(d,J=1.2Hz,1H),3.87(s,3H),3.75(s,3H),1.97(d,J=1.1Hz,3H).13C NMR(125MHz,CDCl3)δ159.8,154.2,145.0,134.7,129.1,127.4,124.0,121.4,118.5,115.2,114.3,55.5,55.5,10.1。
Claims (10)
1.一种式(III)所示多取代2-氨基咪唑化合物的制备方法,其特征在于,所述制备方法为:在非质子极性溶剂中,25~125℃温度条件下,式(I)所示炔丙胺和式(II)所示碳二亚胺在碱性物质的作用下进行环合反应,TLC跟踪监测至反应完全,之后反应液经后处理,得到所述多取代2-氨基咪唑化合物;
所述非质子极性溶剂为甲苯、二甲基亚砜、N,N-二甲基甲酰胺、乙腈或四氢呋喃;所述碱性物质为叔丁醇钾、乙醇钠、乙醇钾、甲醇钠、K3PO4、KOH、NaOH、K2CO3、Na2CO3或Cs2CO3;所述式(I)所示炔丙胺与式(II)所示碳二亚胺的投料物质的量之比为1:0.8~1.2;所述式(II)所示碳二亚胺与碱性物质的投料物质的量之比为1:1.0~1.8;
式(II)或式(III)中,R1、R2各自独立为:氢、苯基、对甲基苯基、对甲氧基苯基、对氯苯基、对溴苯基或C4-C10烷基;
式(I)或式(III)中,R3、R4各自独立为:氢或C1-C6烷基。
2.如权利要求1所述的制备方法,其特征在于,式(II)或式(III)中,所述R1、R2各自独立为:苯基、对甲基苯基、对氯苯基、对溴苯基或C4-C6烷基;式(I)或式(III)中,所述R3、R4各自独立为:氢或C1-C4烷基。
3.如权利要求1所述的制备方法,其特征在于,式(II)或式(III)中,所述R1、R2各自独立为:对氯苯基或环己烷基;式(I)或式(III)中,所述R3、R4各自独立为:氢或甲基。
4.如权利要求1所述的制备方法,其特征在于,所述非质子极性溶剂的体积用量以式(II)所示碳二亚胺的物质的量计为4~7mL/mmol。
5.如权利要求1所述的制备方法,其特征在于,所述非质子极性溶剂为二甲基亚砜或N,N-二甲基甲酰胺。
6.如权利要求1所述的制备方法,其特征在于,所述碱性物质为甲醇钠、NaOH、KOH或Na2CO3。
7.如权利要求1所述的制备方法,其特征在于,所述式(II)所示碳二亚胺与碱性物质的投料物质的量之比为1:1.0。
8.如权利要求1所述的制备方法,其特征在于,所述环合反应的温度为60~100℃,反应时间为2~6h。
9.如权利要求1所述的制备方法,其特征在于,所述反应液后处理的方法为:反应完成后,待反应液冷却至室温,搅拌下向反应液中加入15wt%氯化铵水溶液调节pH至7.0~7.2,然后用乙酸乙酯萃取,萃取所得有机层合并后,经饱和食盐水洗涤、无水硫酸钠干燥、旋转蒸发浓缩得到浓缩物,取浓缩物用体积比10~5:1的石油醚和有机碱混合液作为展开剂进行薄层色谱法分离,得到所述多取代-2-氨基咪唑化合物;所述有机碱为三乙胺、吡啶、N-甲基吗啉或四甲基乙二胺。
10.如权利要求1所述的制备方法,其特征在于,所述制备方法为:
将式(I)所示炔丙胺与非质子极性溶剂混合,然后缓慢滴加式(II)所示碳二亚胺,滴完后在25~40℃下搅拌反应1h,再加入碱性物质,升温至70~90℃搅拌反应2~4h,TLC跟踪监测至反应完全,待反应液冷却至室温,在搅拌下向反应液中加入15wt%氯化铵水溶液调节pH至7.0~7.2,然后用乙酸乙酯萃取三次,萃取所得有机层合并后,经饱和食盐水洗涤、无水硫酸钠干燥、旋转蒸发浓缩得到浓缩物,取浓缩物用体积比10:1的石油醚和三乙胺混合液作为展开剂进行薄层色谱法分离,得到所述多取代-2-氨基咪唑化合物;
所述非质子极性溶剂为二甲基亚砜或N,N-二甲基甲酰胺;所述碱性物质为甲醇钠、NaOH、KOH或Na2CO3;所述式(I)所示炔丙胺与式(II)所示碳二亚胺的投料物质的量之比为1:0.8~1.2;所述式(II)所示碳二亚胺与碱性物质的投料物质的量之比为1:1.0;所述非质子极性溶剂的体积用量以式(II)所示碳二亚胺的物质的量计为4~7mL/mmol。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510406762.6A CN105037271B (zh) | 2015-07-10 | 2015-07-10 | 一种多取代2‑氨基咪唑化合物的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510406762.6A CN105037271B (zh) | 2015-07-10 | 2015-07-10 | 一种多取代2‑氨基咪唑化合物的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105037271A CN105037271A (zh) | 2015-11-11 |
CN105037271B true CN105037271B (zh) | 2017-12-15 |
Family
ID=54444310
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510406762.6A Active CN105037271B (zh) | 2015-07-10 | 2015-07-10 | 一种多取代2‑氨基咪唑化合物的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105037271B (zh) |
-
2015
- 2015-07-10 CN CN201510406762.6A patent/CN105037271B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN105037271A (zh) | 2015-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3567043B1 (en) | 2-[[5-[(4-hydroxy-3-chloro-2-methyl)-phenyl]-thieno[2,3-d]pyrimidin-4-yl]oxy]-3-(2-methoxybenzene)propanoic acid derivatives as mcl-1 and bcl-2 inhibitors for treating cancer | |
CN103232365B (zh) | 一种西弗碱类化合物、合成方法及用途 | |
CN103664561B (zh) | 一种叶菌唑及其中间体的制备方法 | |
CN102134176A (zh) | 一种由卤代芳烃制备芳胺的新方法 | |
CN103524489B (zh) | 2‑氯‑5‑((2‑(硝基亚甲基)咪唑烷‑1‑基)甲基)吡啶的合成工艺 | |
CN105037271B (zh) | 一种多取代2‑氨基咪唑化合物的制备方法 | |
CN105601528A (zh) | 一类以ent-贝叶烷型二萜为手性臂的分子钳化合物及其制备方法和应用 | |
CN106946880B (zh) | 一种制备瑞博西尼中间体的方法 | |
CN105399644A (zh) | 一类以(1s,2s)-1,2-环己二胺为隔离基、以异斯特维醇为手性臂的分子钳化合物及其制备方法和应用 | |
CN105367441A (zh) | 用于合成恩杂鲁胺的新化合物 | |
Morita et al. | Novel building blocks for crystal engineering: the first synthesis of oligo (imidazole) s | |
CN105622507A (zh) | 一种萘酰亚胺衍生物及其制备方法和应用 | |
CN105085510A (zh) | 一种(s)-4-氧代-2-(噻唑烷-3-羰基)吡咯烷-1-羧酸叔丁酯的制备方法 | |
CN107163036A (zh) | 一种含噻唑环5,6‑二取代吡啶‑2‑酮化合物及其制备方法 | |
CN105130923A (zh) | 一种多取代2-亚氨基噻唑类化合物的制备方法 | |
CN106542973A (zh) | 他司美琼中间体及其制备方法 | |
CN105732454A (zh) | 一种l-焦谷氨酸苄酯的生产工艺 | |
CN101837302B (zh) | 一种手性咪唑啉酮类离子液体催化剂的制备方法 | |
CN110218192A (zh) | 一种2-氨基-4,6-二甲氧基嘧啶的制备方法 | |
Srimurugan et al. | Microwave assisted synthesis of 72-membered chiral hexanuclear [6+ 6] macrocyclic Schiff base | |
CN102786466A (zh) | 一种手性Salan配体的合成方法 | |
CN112745314B (zh) | 一种具有特异性抑制HIF-2α作用的芳香胺化合物的制备合成方法 | |
CN103254250B (zh) | 二茂铁基吡嗪环钯氮杂环卡宾化合物及其制备方法和用途 | |
EP4052759A1 (en) | Fluorine-containing pyrimidine compound and manufacturing method for same | |
CN118405969A (zh) | 一种仙鹤草酚f的合成方法及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |